Osteogenic protein 1 device increases bone formation and bone graft resorption around cementless implants

Jensen, Thomas Bo; Overgaard, Søren; Lind, Martin; Rahbek, Ole; Bünger, Cody; Søballe, Kjeld

doi:10.1080/000164702317281378

Cited by 56 publications

(47 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on previous experiments with bovine Colloss, we know that doses that are too high can give adversely increased allograft remodeling, causing a decline in implant fixation (Baas et al 2006). Extreme resorption has been observed in other experimental studies using OP-1/rhBMP7 (Jensen et al 2002, Jeppsson et al 2003) and rhBMP2 (Baas et al 2008) with allograft, and could explain the early failures of revision THR where allograft and OP-1 were used in combination (Kärrholm et al 2006). This has raised the question of whether adjuvant therapies with BMPs mainly raise the overall bone turnover at its application site, rather than favoring an anabolic increase in new bone formation (Little et al 2007).…”

Section: Discussionmentioning

confidence: 99%

“…Our experimental model was designed to study the early fixation and osseointegration of an uncemented implant component inserted into a bed of impacted graft material (Lind et al 2001, Jensen et al 2002. We used dogs for the experiment because their epiphyseal cancellous bone closely resembles the composition, density, and quality of human bone (Aerssens et al 1998).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ceramic bone graft substitute with equine bone protein extract is comparable to allograft in terms of implant fixation: A study in dogs

et al. 2008

Self Cite

View full text Add to dashboard Cite

Background and purpose We studied whether osseointegration and fixation of plasma-sprayed titanium implants grafted with β-TCP granules (Ossaplast) can be improved by adding an osteogenic signal (Colloss E). The results were compared to implants grafted with fresh frozen morselized allograft with and without the Colloss E device.Methods 4 porous-coated Ti implants were placed in the proximal humeri in each of 10 dogs. All implants were surrounded by a 2.5-mm defect, which was grafted with: (A) β-TCP, (B) β-TCP + 20 mg Colloss E, (C) allograft, or (D) allograft + 20 mg Colloss E. The observation time was 4 weeks.Results Mechanical testing showed that the β-TCP group with Colloss E was twice as well fixed as the control group grafted with β-TCP granules alone, and comparable to both allograft groups. We found that every control implant in the β-TCP grafted group was covered by a dense fibrous membrane. No fibrous tissue was seen in the β-TCP group augmented with Colloss. These implants were well osseointegrated, with new bone covering 10-25% of the implant surface. Both treated groups had increased graft resorption compared to their respective control groups. Colloss E had no effect on new bone formation or fibrous tissue reduction around the allografted implants.Interpretation The Colloss E device improved early osseointegration of implants grafted with β-TCP granules and increased their mechanical implant fixation to the level of allografted implants. The experiment

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Ceramic bone graft substitute with equine bone protein extract is comparable to allograft in terms of implant fixation: A study in dogs

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…If there is rapid revascularization, resorption that is too fast might jeopardize the stability. According to Jensen et al (2002), OP-1 may enhance bone formation in dogs, but also accelerates bone resorption in the early phase after grafting. Jeppson et al (2003) studied bone formation in rats using a conduction chamber.…”

Section: Discussionmentioning

confidence: 99%

Mixing bone graft with OP-1 does not improve cup or stem fixation in revision surgery of the hip: 5-year follow-up of 10 acetabular and 11 femoral study cases and 40 control cases

et al. 2006

View full text Add to dashboard Cite

“…49,[217][218][219][220][221] Administration of growth factors and other bioactive molecules to promote bone formation and repair has achieved promising results in several preclinical and clinical models. [222][223][224][225][226][227] A variety of administration methods have been investigated including: bolus injection, surface adsorbed protein release, osmotic pumps, and controlled release from biodegradable scaffolds. The efficacy of the delivery vehicle relies on its ability to provide the appropriate dose over the appropriate therapeutic time frame.…”

Section: Localized Bioactive Molecule and Drug Delivery In Bone Repairmentioning

confidence: 99%

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Porter

Ruckh

Popat

2009

Biotechnology Progress

685

499

View full text Add to dashboard Cite

Critical‐sized defects in bone, whether induced by primary tumor resection, trauma, or selective surgery have in many cases presented insurmountable challenges to the current gold standard treatment for bone repair. The primary purpose of a tissue‐engineered scaffold is to use engineering principles to incite and promote the natural healing process of bone which does not occur in critical‐sized defects. A synthetic bone scaffold must be biocompatible, biodegradable to allow native tissue integration, and mimic the multidimensional hierarchical structure of native bone. In addition to being physically and chemically biomimetic, an ideal scaffold is capable of eluting bioactive molecules (e.g., BMPs, TGF‐βs, etc., to accelerate extracellular matrix production and tissue integration) or drugs (e.g., antibiotics, cisplatin, etc., to prevent undesired biological response such as sepsis or cancer recurrence) in a temporally and spatially controlled manner. Various biomaterials including ceramics, metals, polymers, and composites have been investigated for their potential as bone scaffold materials. However, due to their tunable physiochemical properties, biocompatibility, and controllable biodegradability, polymers have emerged as the principal material in bone tissue engineering. This article briefly reviews the physiological and anatomical characteristics of native bone, describes key technologies in mimicking the physical and chemical environment of bone using synthetic materials, and provides an overview of local drug delivery as it pertains to bone tissue engineering is included. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009

show abstract

Osteogenic protein 1 device increases bone formation and bone graft resorption around cementless implants

Abstract: (2002) Osteogenic protein 1 device increases bone formation and bone graft resorption around cementless implants,

Cited by 56 publications

References 36 publications

Ceramic bone graft substitute with equine bone protein extract is comparable to allograft in terms of implant fixation: A study in dogs

Ceramic bone graft substitute with equine bone protein extract is comparable to allograft in terms of implant fixation: A study in dogs

Mixing bone graft with OP-1 does not improve cup or stem fixation in revision surgery of the hip: 5-year follow-up of 10 acetabular and 11 femoral study cases and 40 control cases

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Contact Info

Product

Resources

About